Thalomid Articles
Hematologist-oncologists view Velcade more favorably than Revlimid or Thalomid for multiple myeloma; report
1 November 2011
UK NICE backing for Celgene and Janssen multiple myeloma drugs, Thalidomide and Velcade; FDA fast-tracks Istodax sNDA
20 June 2011
Draft guidance from UK’s NICE recommends Celgene and Janssen Cilag multiple myeloma drugs; Sanofi-Aventis’ Multaq approved for AF
27 August 2010
Celgene swings back to profit in 1st qtr
5 May 2009
Celgene falls up to 17% on low 1st-qtr forecast
3 April 2009
Zolinza/Velcade combo enters Ph IIb MM trial
26 January 2009
Celgene's 3rd-qtr profit triples on drug sales
17 November 2008
Celgene profits double on rocketing sales
11 August 2008
Celgene posts 1st-qtr loss on Pharmion costs
19 May 2008
EC clears Celgene's Thalidomide in MM
28 April 2008
CHMP issues positive approval opinions
4 February 2008
Celgene's
14 January 2008
Velcade boosts remission rates in MM
17 December 2007
Thalidomide improves survival rate in MM
15 October 2007
Thalidomide AE reports defended by Brazil govt
15 October 2007
EntreMed secures $20M financing
24 September 2007
Heated response for Israel drug safety reform
13 August 2007
Celegene's 2nd-qtr 2007 income soars 187.2%
6 August 2007
Millennium initiates Ph III trial of Velcade
23 July 2007
Gruenenthal goes to law over TV film
2 July 2007
Celgene's 1st-qtr 2007 net income soars 61.4%
28 May 2007
EMEA accepts Pharmion's Thalidomide MA
12 March 2007
Pharmion submits thalidomide to EMEA
29 January 2007
Off-label drug use defended by US think-tank
28 August 2006
US FDA clears Celgene's Revlimid for MM
10 July 2006
Strong data for Pharmion's thalidomide in MM
19 June 2006
Celgene's Thalomid gets FDA OK for MM
5 June 2006
Celgene's profits nosedive 82%
6 February 2006
Strong animal data for Callisto's Atipromod
4 July 2005
Celgene posts record 1st-qtr EPS
9 May 2005
Vidaza launch boost Pharmion's 4th qtr
21 February 2005
Approvable letter for Celgene's Thalomid
1 November 2004
Pharmion's Vidaza sales $20.4M in launch quarter
1 November 2004
Celgene's adverse drug reports were late, says FDA
30 August 2004
Celgene raises 2004 guidance on 2nd-qtr
2 August 2004
Thalomid effective in prostate cancer
12 July 2004
Turkish approval for Thalidomide Pharmion
14 June 2004
Celgene's Thalomid on track for new use
1 March 2004
Celgene's profits below forecast
19 January 2004
Thalidomide gets OK in New Zealand for MM
5 January 2004
Pharmion's thalidomide approved in Australia
20 October 2003
EntreMed and Celgene expand partnership
14 April 2003
Celgene forecasts profit in 2003
17 March 2003
Entremed licenses thalidomide rights to Celgene
6 January 2003
Millennium cancer drugs fast-tracked in USA
10 June 2002
Zambon acquires Laphal business
27 May 2002
Celgene hit by need for another Thalomid trial
18 March 2002
Celgene net income leaps 81%
4 February 2002
Millennium says molecular therapy for multiple myeloma halts disease
11 December 2001
Celgene's Revimid promising in myeloma
11 December 2001
Pharmion placement raises $65 million
6 December 2001
Drug Royalty takes a royalty stake in Thalomid
15 October 2001
Celgene's Revimid an orphan drug, says FDA
9 October 2001
Celgene drug promises activity in solid tumors
8 June 2001
Thalomid trial in myeloma delayed?
9 April 2001
EntreMed in spotlight on Endostatin hopes
21 January 2000
Thalidomide potential in Crohn's?
2 December 1999
Celgene boosted on thalidomide data
24 November 1999
FDA OKs expanded indications for B-MS' Zerit and Videx
10 September 1999
Thalidomide of value in multiple myeloma
8 September 1999
Thalidomide to be investigated in colorectal cancer
6 August 1999
US NCI trial Celgene's Thalomid in NSCL cancer
29 March 1999
Celgene Buys Out EntreMed From Thalidomide
16 December 1998
Celegene receives orphan drug designation from FDA for Thalomid
29 October 1998
Thalomid Debuts On US Market
6 October 1998
Thalomid Distribution To Start
22 September 1998
Thalomid In AIDS Wasting
29 July 1998
Thalidomide Closer To US Market For Leprosy
10 September 1997
Further Application For Thalidomide
3 March 1997
Significant Weight Gain With Celgene's Synovir
10 February 1997
Celgene Completes Trial With Thalidomide
21 October 1996
New Thalidomide Trial Started
29 April 1996
Thalidomide Enters Cancer Testing Program At NCI
15 April 1996
Japanese Drug Law "Failed To Stop HIV Tragedy"
8 April 1996
US GAO urges Caution Over EU Device Approvals
18 March 1996
Bristol-Myers Squibb Buys Hungarian Firm
18 December 1995
Celgene: Synovir news
4 December 1995
Euro Parliamentarian To Probe Thalidomide
4 December 1995
More Thalidomide Trials On Horizon
9 October 1995
US Govt Starts CenTNF Plus IL-2 Study In HIV-1
2 October 1995
Celgene's Synovir
4 September 1995
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- CIS countries prepare for the introduction of drug reimbursement schemes
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
